Related Experiment Videos
Angiosarcomas--clinical profile, pathology and management.
1Department of Radiation Oncology and Anatomical Pathology, University of the Witwatersrand, South African Institute for Medical Research, Johannesburg.
Summary
Primary angiosarcomas are aggressive tumors. Complete surgical excision is the preferred treatment, though the prognosis remains poor for these rare endothelial cell cancers.
Area of Science:
- Oncology
- Pathology
- Surgical Oncology
Background:
- Angiosarcomas are rare, aggressive malignant tumors originating from endothelial cells.
- Primary angiosarcomas can occur in various locations, including the breast, skin, intestine, and brain.
- Understanding the management and prognosis of primary angiosarcomas is crucial for effective patient care.
Purpose of the Study:
- To review the clinical management and outcomes of patients with primary angiosarcomas.
- To evaluate the effectiveness of complete surgical excision as the primary treatment modality.
- To analyze prognostic factors and survival rates in patients with angiosarcomas.
Main Methods:
- Retrospective review of 8 patients with primary angiosarcomas treated between 1982 and 1995.
- Histopathological review of slides for 6 patients to confirm diagnosis.
- Analysis of treatment modalities, including complete excision and postoperative radiotherapy.
- Assessment of patient outcomes, including survival and disease status.
Main Results:
- Five of six reviewed cases were confirmed as angiosarcomas.
- The most common site was the breast (4 patients), with single cases in the skin, intestine, and brain.
- Four patients died within 4 months of diagnosis; three patients are alive with 2 showing no evidence of disease.
- Complete surgical excision was the primary management strategy.
Conclusions:
- Angiosarcomas are aggressive malignancies with a generally poor prognosis.
- Complete surgical excision is the treatment of choice for angiosarcomas.
- Multidisciplinary management and further research are needed to improve outcomes for this rare cancer.